Avacta Group (LON:AVCT) Trading Down 7.4% - What's Next?

Key Points

• Avacta Group Plc shares declined by 7.4% during mid-day trading on Friday, reaching a low of GBX 47 ($0.62) before closing at GBX 47.70 ($0.63).
• The company reported a negative net margin of 114.45% and a negative return on equity of 74.00%, indicating ongoing financial challenges.
• Analysts predict that Avacta Group will post -9.90 earnings per share for the current year, signaling expectations of further losses.

Avacta Group Plc (LON:AVCT - Get Free Report) fell 7.4% during mid-day trading on Friday . The stock traded as low as GBX 47 ($0.62) and last traded at GBX 47.70 ($0.63). 2,786,073 shares were traded during trading, an increase of 34% from the average session volume of 2,075,455 shares. The stock had previously closed at GBX 51.50 ($0.68).

Avacta Group Price Performance

The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53. The firm has a market cap of £181.21 million, a price-to-earnings ratio of -6.14 and a beta of 1.12. The company's 50-day moving average is GBX 34.67 and its 200-day moving average is GBX 37.78.

Avacta Group (LON:AVCT - Get Free Report) last issued its earnings results on Friday, June 6th. The biotechnology company reported GBX (8.54) (($0.11)) earnings per share for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. Equities research analysts predict that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.